Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
KIN's Cash-to-Debt is ranked higher than
75% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. KIN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
KIN' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
KIN's Interest Coverage is ranked higher than
67% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. KIN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KIN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 34.94
WACC vs ROIC
3.59%
-662.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -34.77
KIN's ROE % is ranked higher than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. KIN: -34.77 )
Ranked among companies with meaningful ROE % only.
KIN' s ROE % Range Over the Past 10 Years
Min: -34.77  Med: -32.19 Max: -13.34
Current: -34.77
-34.77
-13.34
ROA % -33.44
KIN's ROA % is ranked lower than
52% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. KIN: -33.44 )
Ranked among companies with meaningful ROA % only.
KIN' s ROA % Range Over the Past 10 Years
Min: -33.44  Med: -29.89 Max: -12.68
Current: -33.44
-33.44
-12.68
ROC (Joel Greenblatt) % -1092.05
KIN's ROC (Joel Greenblatt) % is ranked lower than
62% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. KIN: -1092.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
KIN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -70316.67  Med: -8371.98 Max: -1092.05
Current: -1092.05
-70316.67
-1092.05
3-Year EBITDA Growth Rate 0.30
KIN's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. KIN: 0.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
KIN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0.15 Max: 0.3
Current: 0.3
0
0.3
GuruFocus has detected 1 Warning Sign with Kindred Biosciences Inc $KIN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» KIN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

KIN Guru Trades in Q2 2016

Jim Simons 302,700 sh (+38.92%)
John Rogers 3,695,576 sh (+3.01%)
Seth Klarman 3,013,848 sh (unchged)
Chuck Royce 148,000 sh (unchged)
» More
Q3 2016

KIN Guru Trades in Q3 2016

Jim Simons 331,600 sh (+9.55%)
John Rogers 3,835,163 sh (+3.78%)
Chuck Royce 148,000 sh (unchged)
Seth Klarman 3,011,584 sh (-0.08%)
» More
Q4 2016

KIN Guru Trades in Q4 2016

Jim Simons 351,600 sh (+6.03%)
John Rogers 3,940,859 sh (+2.76%)
Chuck Royce 148,000 sh (unchged)
Seth Klarman Sold Out
» More
Q1 2017

KIN Guru Trades in Q1 2017

Jim Simons 504,800 sh (+43.57%)
Chuck Royce 126,000 sh (-14.86%)
John Rogers 2,976,322 sh (-24.48%)
» More
» Details

Insider Trades

Latest Guru Trades with KIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541940    SIC: 742
Compare:NAS:DRNA, NAS:BDSI, NAS:AVXL, NAS:CNAT, NAS:ATHX, OTCPK:CNBX, NAS:MACK, NAS:ALT, AMEX:AST, NAS:XBIT, NAS:GEMP, NAS:MNOV, TSX:VBV, NAS:CDXC, NAS:TRVN, NAS:MDGL, NAS:OCUL, NAS:SRNE, NAS:CASC, TSX:HSM » details
Traded in other countries:17K.Germany,
Headquarter Location:USA
Kindred Biosciences Inc is a development-stage biopharmaceutical company. It is engaged in saving and improving the lives of pets. The Company's product candidates are SentiKind, KIND-010 and KIND-012.

Kindred Biosciences Inc is a development stage biopharmaceutical company developing pet care products. The company identifies compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. Kindred Biosciences has a pipeline of novel drugs and biologics in development across various therapeutic classes. Its pipeline products include Mirataz, Zimeta, KIND-014, KIND-015, epoCat, Anti-Interleukin anibodeis, Anti-CD20, Anti-IgE, Anti-VEGF, Anti-TNF, and Checkpoint Inhibitors.

Ratios

vs
industry
vs
history
PB Ratio 2.52
KIN's PB Ratio is ranked higher than
64% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. KIN: 2.52 )
Ranked among companies with meaningful PB Ratio only.
KIN' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.05
Current: 2.52
0
3.05
EV-to-EBIT -4.90
KIN's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. KIN: -4.90 )
Ranked among companies with meaningful EV-to-EBIT only.
KIN' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.53  Med: 0 Max: 0
Current: -4.9
-6.53
0
EV-to-EBITDA -4.93
KIN's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. KIN: -4.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
KIN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.57  Med: 0 Max: 0
Current: -4.93
-6.57
0
Current Ratio 24.03
KIN's Current Ratio is ranked higher than
95% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. KIN: 24.03 )
Ranked among companies with meaningful Current Ratio only.
KIN' s Current Ratio Range Over the Past 10 Years
Min: 10.63  Med: 28.95 Max: 45.03
Current: 24.03
10.63
45.03
Quick Ratio 24.03
KIN's Quick Ratio is ranked higher than
95% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. KIN: 24.03 )
Ranked among companies with meaningful Quick Ratio only.
KIN' s Quick Ratio Range Over the Past 10 Years
Min: 10.63  Med: 28.95 Max: 45.03
Current: 24.03
10.63
45.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.80
KIN's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. KIN: -9.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KIN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.8  Med: -4.9 Max: 0
Current: -9.8
-9.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.87
KIN's Price-to-Net-Cash is ranked higher than
78% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. KIN: 2.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
KIN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.97  Med: 1.58 Max: 5.19
Current: 2.87
0.97
5.19
Price-to-Net-Current-Asset-Value 2.72
KIN's Price-to-Net-Current-Asset-Value is ranked higher than
78% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. KIN: 2.72 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KIN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.96  Med: 1.56 Max: 5.15
Current: 2.72
0.96
5.15
Price-to-Tangible-Book 2.51
KIN's Price-to-Tangible-Book is ranked higher than
71% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. KIN: 2.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KIN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.88  Med: 1.53 Max: 5.14
Current: 2.51
0.88
5.14
Earnings Yield (Greenblatt) % -20.41
KIN's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. KIN: -20.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KIN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2000  Med: 0 Max: 0
Current: -20.41
-2000
0

More Statistics

EPS (TTM) $ -1.13
Beta0.22
Short Percentage of Float0.77%
52-Week Range $3.83 - 9.65
Shares Outstanding (Mil)23.31

Analyst Estimate

Dec18
Revenue (Mil $)
EPS ($) -0.75
EPS without NRI ($) -0.75
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for KIN

Headlines

Articles On GuruFocus.com
KindredBio Announces Pricing of Public Offering Jul 12 2017 
KindredBio Announces Proposed Public Offering of Common Stock Jul 11 2017 
Kindred Biosciences Added to the Russell 2000 Index Jun 15 2017 
Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Inte May 30 2017 
Kindred Biosciences to Present at 7th Annual LD Micro Invitational May 24 2017 
Kindred Biosciences Announces First Quarter 2017 Financial Results May 03 2017 
Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral May 01 2017 
Kindred Biosciences to Announce First Quarter 2017 Financial Results Apr 24 2017 
10 Stocks John Rogers Keeps Buying Sep 27 2016 
John Rogers Invests in Bristow Group, Kindred Biosciences Apr 08 2016 

More From Other Websites
Kindred Biosciences to Announce Second Quarter 2017 Financial Results Jul 24 2017
Zacks.com featured highlights: Logitech International, Herman Miller, Diodes, Willdan Group and... Jul 20 2017
Kindred Biosciences' stock drops after public stock offering Jul 12 2017
KindredBio Announces Pricing of Public Offering Jul 12 2017
KindredBio Announces Proposed Public Offering of Common Stock Jul 11 2017
Will Kindred Biosciences (KIN) Continue to Surge Higher? Jun 30 2017
Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial... Jun 26 2017
Kindred Biosciences Added to the Russell 2000 Index Jun 15 2017
Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary... May 30 2017
Kindred Biosciences to Present at 7th Annual LD Micro Invitational May 24 2017
Edited Transcript of KIN earnings conference call or presentation 3-May-17 8:30pm GMT May 11 2017
Kindred Bio reports 1Q loss May 03 2017
Kindred Biosciences Announces First Quarter 2017 Financial Results May 03 2017
Investor Network: Kindred Biosciences, Inc. to Host Earnings Call May 03 2017
Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral... May 01 2017
Kindred Biosciences to Announce First Quarter 2017 Financial Results Apr 24 2017
Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit Mar 16 2017
Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor... Mar 07 2017
Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}